Retina Consultants of America (RCA) has added South Carolina-based Palmetto Retina Center (PRC) to its consortium of practices. This is the seventh retina specialty practice to join RCA.
Palmetto Retina Center is comprised of five retina specialists across six offices serving South Carolina. Locations include West Columbia, Downtown Columbia, Orangeburg, Sumter, Aiken, and Florence.
“We are thrilled to be joining Retina Consultants of America. Palmetto Retina Center was formed with a commitment to the highest level of medical surgical care and an emphasis on education and research,” said W. Lloyd Clark, MD, Palmetto Retina Center, Assistant Clinical Professor of Ophthalmology at the University of South Carolina School of Medicine, said in a company news release. “Our collaborative work in drug development helped us form strong relationships with many of the founding members of RCA, making a partnership with RCA a perfect fit. What is emerging in RCA is a world-class group of retinal specialists, and we could not pass up the opportunity to join.”
Formed by Webster Equity Partners and headquartered in Southlake, Texas, RCA is partnering with retina specialists who seek a strategic partner with the capital resources and expertise to invest in their practice infrastructure and position them for continued growth in their markets. RCA is unique in that this is the first horizontal alliance in the eyecare field focused solely on retinal care, according to a news release.
“Our continued growth with premier retina physicians demonstrates our unique horizontal alliance model resonates with the highest quality physicians,” Robert Grabow, CEO of RCA, said in the news release. “We are pleased to have Dr. Clark and the team at Palmetto Retina join RCA. Their long history of collaborating with many of our current practices and commitment to research and advancing the field of retinal care makes them a perfect addition to our alliance.”
RCA is governed by a Medical Leadership Board that is co-chaired by Joel Pearlman, MD, PhD and David M. Brown, MD. Drs. Pearlman and Brown are both leaders in clinical trials that led to the development of anti-VEGF injections for the treatment of macular degeneration, diabetic retinopathy and retinal vein occlusion.